Drugs
Every drug, from preclinical program to approved product
Coverage
| Stage | What you get |
|---|---|
| Approved | Every drug approved by the FDA, EMA, or Health Canada: 4,800+ of them |
| Clinical-stage | Every drug tested in a ClinicalTrials.gov trial since 2020, plus the experimental assets of every company with a clinical-stage program: 17,400+ investigational and 9,200+ experimental compounds |
| Preclinical | Every preclinical program companies have disclosed in SEC filings, press releases, and pipeline pages: 39,700+ programs, half with no named asset yet, showing activity before a drug exists |
Where it connects
Drug record
Dolutegravir
DB08930
Targets
What each drug binds, and whether it activates or blocks it
nameGag-Pol polyprotein
gene_namepol
uniprotkb_accessionQ7ZJM1
action_typeinhibitor
pharmacological_actionyes
organism_nameHuman immunodeficiency virus 1
cellular_locationnull
+17 more relationships
Diseases
Approved and investigational indications
titleHuman Immunodeficiency Virus Type 1 (HIV-1) Infection
drugbank_idDBCOND0045921
meddra_idllt/10068341
snomed_idc/40780007
icd10_idc/B20
1 of 1 indicated condition
Clinical trials
Every trial that tested it, with phase, status, and posted results
NCT00042289
NCT00555035
NCT00631592
NCT00708110
NCT00726336
NCT00774111
NCT00774735
NCT00796263
NCT00828763
NCT00858455
+297 more
NCT00631592.phases[1]
NCT00631592.statuscompleted
NCT00796263.phases[3]
NCT00796263.statusrecruiting
NCT00042289.phases[]
Companies
The owner today, through every merger and acquisition
drugDolutegravir
trialNCT00631592
sponsor.title (as filed)ViiV Healthcareindependent subsidiary
parents[0].nameGlaxoSmithKline
Products
Every brand, strength, and package it's sold under
product_name[0]ACRIPTEGA
product_name[1]DILTRA
product_name[2]DINISVIR 50
product_name[3]Dolutegravir
+45 more
Zoom in
| drug | drug_drugbank_id | half-life as reported | normalized (h) |
|---|---|---|---|
| Semaglutide | DB13928 | 168 hours | 168 |
| Albiglutide | DB09043 | 4–7 days | 96–168 |
| Tirzepatide | DB15171 | 5 days | 120 |
| Dulaglutide | DB09045 | 5 days | 120 |
| Dulaglutide | DB09045 | 3.75 days | 89.9 |
| Liraglutide | DB06655 | 13 hours | 13 |
| Lixisenatide | DB09265 | 3 hours | 3 |
| Exenatide | DB01276 | 2.4 hours | 2.4 |
| kind | condition | country | max_phase | route | dose_form | age_groups |
|---|---|---|---|---|---|---|
| used_in_combination_to_treat | HIV-1 Infection | US | 4 | Oral | Tablet | adult, pediatric |
| adjunct_therapy_in_treatment_of | HIV-1 Infection | US | 4 | Oral | Tablet, Tablet for suspension | adolescent, pediatric |
| adjunct_therapy_in_treatment_of | HIV-1 Infection | US | 4 | Oral | Tablet, Tablet for suspension | adult |
| used_in_combination_to_treat | HIV-1 Infection | US | 4 | Oral | Tablet | adult |
+8 more indications
| program_drugbank_id | entity | raw_phase | raw_status | targets | companies |
|---|---|---|---|---|---|
| DBPRG00153911 | HCW11-006 | preclinical | null | IL7, IL15, IL21 | HCW Biologics; Akron Biotech |
| DBPRG00137411 | null | preclinical | active | gp120 | California Institute of Technology; Bill & Melinda Gates Foundation; Absci; Caltech |
| DBPRG00143637 | ASN3013 | preclinical | active | env | Absci; California Institute of Technology; Bill & Melinda Gates Foundation |
| DBPRG00040886 | CRV431 | preclinical | active | cyclophilin, cyclophilins | Hepion Pharmaceuticals |
+6 more programs
| field | value |
|---|---|
| moldb_formula | C20H19F2N3O5 |
| molecular_weight | 419.3788 |
| moldb_smiles | [H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C(O)=C3C(=O)N1[C@H](C)CCO2 |
| moldb_inchikey | RHWKPHLQXYSBKR-BMIGLBTASA-N |
| logp | 0.98 |
| polar_surface_area | 99.18 |
| rule_of_five | true |
| salts[0] | Dolutegravir sodium · DBSALT000943 · CAS 1051375-19-9 |
| interacting_drug | drug_drugbank_id | severity | evidence | action |
|---|---|---|---|---|
| Dofetilide | DB00204 | major | level_1 | increase_serum_concentration |
| Metformin | DB00331 | moderate | level_1 | increase_serum_concentration |
| Pravastatin | DB00175 | moderate | level_2 | decrease_dynamics |
| Valproic acid | DB00313 | moderate | level_2 | decrease_dynamics |
| Etanercept | DB00005 | minor | level_2 | increase_specific_effects |
+934 more interactions
| effect | condition ID | region | route | arm | comparator | percent |
|---|---|---|---|---|---|---|
| Insomnia | DBCOND0017531 | US | Oral | experimental | — | <1% |
| Insomnia | DBCOND0017531 | US | Oral | comparator | dolutegravir/lamivudine | 3% |
| Diarrhea and Loose Stools | DBCOND0126047 | US | Oral | experimental | — | 2% |
| increased alanine aminotransferase (ALT) | DBCOND0102242 | US | Oral | experimental | — | 9% |
+86 more adverse effects
| field | value |
|---|---|
| name | Dolutegravir |
| synonyms | Dolutegravir, GSK1349572, GSK572, S-349572, S/GSK1349572 |
| cas_number | 1051375-16-6 |
| unii | DKO1W9H7M1 |
| chembl_id | CHEMBL1229211 |
| rxnorm_id | 1433868 |
| pubchem_cid | 54726191 |
| atc[3].title | Integrase inhibitors |
Questions it answers
- Which compounds hit my target with a longer half-life than the incumbent? Efficacy and safety benchmarking
- What's in development against this mechanism that hasn't reached a trial yet? Landscape and whitespace analysis
- How do safety profiles compare across a drug class? Efficacy and safety benchmarking
All figures pulled as of November 2026.